Results 11 to 20 of about 269,227 (256)

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Haematologica, 2013
Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Aziz Nazha, Hagop Kantarjian, Preetesh Jain, Carlos Romo, Elias Jabbour, Alfonso Quintas-Cardama, Raja Luthra, Lynne Abruzzo, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Susan O’Brien, Jorge Cortes   +12 more
doaj   +1 more source

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Frontiers in Pharmacology, 2020
Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa, Ivan Alvarez-Twose   +1 more
doaj   +1 more source

Tyrosine Kinase Inhibitors for the Elderly [PDF]

Journal of Cancer, 2016
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient.
Hohenforst-Schmidt, Wolfgang, Zarogoulidis, Paul, Steinheimer, Michael, Benhassen, Naim, Tsiouda, Theodora, Baka, Sofia, Yarmus, Lonny, Stratakos, Grigoris, Organtzis, John, Pataka, Athanasia, Tsakiridis, Kosmas, Karapantzos, Ilias, Karapantzou, Chrysanthi, Darwiche, Kaid, Zissimopoulos, Athanasios, Pitsiou, Georgia, Zarogoulidis, Konstantinos, Man, Yan-Gao, Rittger, Harald   +18 more
openaire   +3 more sources

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients

Acta Dermato-Venereologica
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation.
Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo   +5 more
doaj   +1 more source

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer

Acta Médica Portuguesa, 2019
The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors.
Andreia Tereso, Luís Carreto, Manuela Baptista, Maria Amélia Almeida   +3 more
doaj   +1 more source

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

Revista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moises M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles   +8 more
doaj   +1 more source

Nilotinib-Associated Destructive Thyroiditis

Case Reports in Endocrinology, 2015
Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala, Monica D. Schwarcz, Michael D. Goldberg, Guy Valiquette, Irene A. Weiss   +4 more
doaj   +1 more source

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

Haematologica, 2013
Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion, Anat Gafter-Gvili, Liat Vidal, Avi Leader, Ron Ram, Adi Shacham-Abulafia, Mical Paul, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani   +9 more
doaj   +1 more source

Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted 
Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors

Chinese Journal of Lung Cancer, 2017
At present the treatment of advanced non-small cell lung cancer enters a targeted era and develops rapidly. New drugs appear constantly. Small molecular tyrosine kinase inhibitors have occupied the biggest piece of the territory, which commonly have a ...
Guowei ZHANG, Huijuan WANG, Zhiyong MA
doaj   +1 more source

Nanomedicine of tyrosine kinase inhibitors

Theranostics, 2021
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Šmídová, Veronika, Michálek, Petr, Goliášová, Zita, Eckschlager, Tomáš, Hodek, Petr, Adam, Vojtěch, Heger, Zbyněk   +6 more
openaire   +3 more sources